文献速递主动脉疾病

腹主动脉瘤患者抗血小板治疗与出血、血栓及动脉瘤增长的关系

Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms.
PubMed 文献 · Ann Vasc Surg · 2026-10-28

单中心回顾性研究纳入886例影像学发现的腹主动脉瘤患者,其中511例(57.7%)接受抗血小板治疗。平均随访1.8年,抗血小板治疗与出血、主要不良心血管事件、静脉血栓栓塞或动脉瘤生长速率均无关联;他汀与死亡率降低相关(HR=0.73,p=0.02)。

要点

  • 抗血小板治疗未增加腹主动脉瘤患者出血风险,但也未降低死亡率、血栓事件或动脉瘤生长。
  • 他汀与死亡率降低独立相关(HR=0.73,p=0.02),而抗血小板药和抗凝药无此关联。
  • 糖尿病与动脉瘤生长速率降低相关,初始直径较大与生长速率及死亡率增加相关。

核心结论

  • 在腹主动脉瘤患者中,抗血小板治疗未观察到与出血风险增加相关,但也未与死亡率、血栓形成或动脉瘤生长降低相关。
  • 他汀与死亡率降低相关,动脉瘤生长速率仅受糖尿病影响,与所研究的任何药物治疗无关。

研究设计与样本

  • 单中心回顾性病历审查,纳入2019—2023年影像学发现的腹主动脉瘤患者886例(73%男性)。
  • 按抗血小板治疗状态比较人口学特征与结局,并用多变量回归分析与死亡率、主要不良心血管事件、出血及动脉瘤生长相关的因素。

主要发现

  • 511例(57.7%)接受抗血小板治疗,其动脉粥样硬化性疾病比例高于未治疗者;未治疗者更多为女性、合并心房颤动且接受抗凝治疗。
  • 平均随访1.8年,抗血小板治疗与出血、主要不良心血管事件、静脉血栓栓塞事件或生长速率均无差异。
  • 校正分析显示他汀与死亡率降低相关(HR=0.73,p=0.02),抗血小板药或抗凝药与死亡率无显著关联。
  • 糖尿病与腹主动脉瘤生长速率降低相关,初始直径较大与生长速率增加及死亡率增加相关。

关键数值与推荐

  • 抗血小板治疗与出血无显著关联(原文未报告具体数值)。
  • 他汀与死亡率降低相关:HR=0.73,p=0.02。
  • 动脉瘤生长速率与任何所研究的药物治疗(包括他汀)均无关联,仅受糖尿病影响。

临床怎么用

  • 对腹主动脉瘤患者处方抗血小板治疗时,无需因出血风险顾虑而避免,但不应期望其降低死亡率、血栓事件或延缓动脉瘤生长。
  • 他汀治疗与死亡率降低相关,可考虑用于腹主动脉瘤患者的综合管理。
  • 动脉瘤生长监测中,糖尿病患者的生长速率可能较低,而初始直径较大者需更密切随访。

局限性

  • 单中心回顾性设计,可能存在选择偏倚和混杂因素。
  • 平均随访时间较短(1.8年),可能不足以观察长期结局。
  • 抗血小板治疗状态基于处方记录,未报告用药依从性或具体药物类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent guidelines recommend considering antiplatelet therapy (class IIb recommendation) for patients with AAAs, but bleeding risk remains a concern. This study aims to investigate the association of antiplatelet therapy with bleeding, thrombosis, and aneurysm growth among patients with AAAs. METHODS: A single-center retrospective chart review of patients with AAA identified on imaging (2019-2023) was performed. Demographics and outcomes were compared by antiplatelet status, and multivariable regression identified factors associated with mortality, MACE, bleeding, and AAA growth. RESULTS: Among 886 (73% male) patients studied, 511 (57.7%) were prescribed antiplatelet therapy. Those prescribed antiplatelet therapy had higher rates of atherosclerotic disease than those not on antiplatelets. Patients not prescribed antiplatelet therapy were more likely to be female, have atrial fibrillation, and be prescribed anticoagulation. At a mean follow-up of 1.8 years, there were no differences in bleeding, major adverse cardiovascular events, venous thromboembolism events, or growth rate associated with antiplatelet prescription. Adjusted analyses showed statins (HR=0.73, p=0.02), but not antiplatelets or anticoagulants, were associated with reduced risk of mortality. Diabetes was associated with decreased AAA growth rate, while larger initial diameter was associated with increased growth rate as well as mortality. CONCLUSIONS: Among patients with AAA, antiplatelet therapy was not observed to be associated with an increase in bleeding risk, but was also not associated with decreased mortality, thrombosis, or aneurysm growth. Statins were observed to be associated with reduced mortality. Aneurysmal growth rate was not associated with any medical therapies studied, including statins, and was only influenced by the presence of diabetes.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Crews B, Li J, Kostiuk V, et al. Antiplatelet Therapy and Bleeding, Thrombosis, and Aneurysm Growth in Patients with Abdominal Aortic Aneurysms. Ann Vasc Surg. 2026. PMID: 42951181. doi:10.1016/j.avsg.2026.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。